An Evolving Biologics Landscape And Driving Innovation And Opportunity

By Tim Roberts, Chief Commercial Officer, PCI Pharma Services

Already growing in importance before the COVID-19 pandemic, the biologics segment is expanding even faster in its wake, with respect to both the level of investment and number of new startups. PCI Pharma Services is keeping pace with the changes and remaining focused on addressing the growing need for outsourcing support by these new small and medium-sized biopharmaceutical companies.

This article explores a more collaborative investment model, how personalized medicines are changing healthcare, the development of novel devices and delivery technologies, and a natural evolution in the CDMO space.